APH vs BBIO · P/E 40, rev $23.09B vs rev $221.9M
Amphenol Corporation (APH) versus BridgeBio Pharma Inc (BBIO) — a side-by-side from cached financials, not a winner call.
Amphenol Corporation (APH) is a electronic components company listed on US.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Latest reported APH revenue for 2025-12-31 was $23.09B. Net income was $4.27B. Revenue was up 51.7% from 2024-12-31 to 2025-12-31. APH currently screens at market cap $170.77B and trailing P/E 39.9.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
APH currently screens at market cap $170.77B and trailing P/E 39.9. BBIO currently screens at market cap $13.24B.
Not investment advice. Open the APH and BBIO stock pages for the full models.
Not investment advice.